Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Clonidine Mucoadhesive Buccal Tablet to Placebo to Prevent Chemoradiotherapy-induced Severe Oral Mucositis in Patients With Oropharyngeal Cancer

NCT04648020 is registered in ClinicalTrials.gov with Monopar Therapeutics as lead sponsor.

NCT NCT04648020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04648020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Clonidine Mucoadhesive Buccal Tablet to Placebo to Prevent Chemoradiotherapy-induced Severe Oral Mucositis in Patients With Oropharyngeal Cancer
Lead sponsor
Monopar Therapeutics
Phase
Phase 2/3
Overall status
Terminated
Start date
February 11, 2021
Completion date
May 14, 2023
Enrollment
190 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

chemoradiotherapy-induced severe oral mucositis